Lucentis ranibizumab: Additional Phase III data

Additional follow-up data from 647 evaluable patients with neovascular AMD who completed the in the double-blind, U.S. Phase III CATT trial showed that intravitreal Lucentis did not lead to a significant improvement in mean visual acuity at 5.5 years (57.7 letters vs. 60.2 letters, p=0.19) or

Read the full 469 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE